Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
HZ.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.69NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.98NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
XBB.1.5.71NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HT.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.90NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
FB.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.18.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.32NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.26.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
FK.1.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1.2.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
CH.1.1.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LP.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LF.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LQ.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LY.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MD.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LZ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MB.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.2.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.50NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
unclassifiableNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KS.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HH.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XCENSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HN.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GU.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GQ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JA.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.5.1.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.2.7.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.9.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.22NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JV.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GE.1.2.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used